Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CELC

Celcuity Inc.

Healthcare | Biotechnology

No licensed closing price on file for CELC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Celcuity Inc. (NASDAQ: CELC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:14 UTC.

What Celcuity Inc. does

Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors, with its lead candidate being gedatolisib, a kinase inhibitor that targets the PI3K/AKT/mTOR signaling pathway. The company is conducting multiple clinical trials of gedatolisib, including a Phase 3 trial called VIKTORIA-1 in hormone receptor-positive breast cancer patients and a Phase 3 trial called VIKTORIA-2 evaluating the drug as a first-line treatment combined with other therapies.

Summarized from Celcuity Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for CELC are available in Oxford Ledge.
Open CELC in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-09
  • 2026-10-09DirectorOption exercise250$1.9K
  • 2026-10-09DirectorStock Option (right to buy)Option exercise-250—
  • 2026-10-05DirectorAward893—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CELC and 5,000+ tickers.

Create a free account — keep CELC
For your agent
GET /api/data?ticker=CELC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt